We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+2.93%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$182M
AUM Growth
-$9.72M
(-5.1%)
Cap. Flow
-$9.6M
Cap. Flow
% of AUM
-5.28%
Top 10 Holdings %
Top 10 Hldgs %
6.2%
Holding
508
New
65
Increased
160
Reduced
215
Closed
68
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Dow Inc
DOW
|
+$1.19M |
| 2 |
Progressive
PGR
|
+$963K |
| 3 |
Hershey
HSY
|
+$960K |
| 4 |
DexCom
DXCM
|
+$934K |
| 5 |
Copart
CPRT
|
+$930K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lennar Class A
LEN
|
+$952K |
| 2 |
TJX Companies
TJX
|
+$909K |
| 3 |
Ameriprise Financial
AMP
|
+$902K |
| 4 |
Abbott
ABT
|
+$892K |
| 5 |
Home Depot
HD
|
+$885K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.65% |
| 2 | Financials | 14.09% |
| 3 | Technology | 11.21% |
| 4 | Energy | 10.21% |
| 5 | Materials | 8.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
401
4D Molecular Therapeutics
FDMT
$502M
| $71.2K | 0.04% |
4,140
-1,591
| -28% | -$30.9K |
|
402
Editas Medicine
EDIT
$399M
| $70.8K | 0.04% |
9,769
-3,751
| -28% | -$33.3K |
|
|
IGMS
403
DELISTED
IGM Biosciences
IGMS
| $70.3K | 0.04% |
5,113
-1,965
| -28% | -$40.6K |
|
404
Invesco Senior Income Trust
VVR
$456M
| $69K | 0.04% |
18,740
-57,421
| -75% | -$223K |
|
405
Lyell Immunopharma
LYEL
$318M
| $67.1K | 0.04% |
1,421
-546
| -28% | -$29.2K |
|
|
RPTX
406
DELISTED
Repare Therapeutics
RPTX
| $67K | 0.04% |
6,808
-2,618
| -28% | -$30K |
|
407
Arcutis Biotherapeutics
ARQT
$3.48B
| $67K | 0.04% |
6,088
-2,335
| -28% | -$33.8K |
|
|
BCYC
408
Bicycle Therapeutics
BCYC
$269M
| $66.9K | 0.04% |
3,145
-1,216
| -28% | -$30.5K |
|
409
Alector
ALEC
$169M
| $66.7K | 0.04% |
10,782
-4,151
| -28% | -$33.8K |
|
410
Caribou Biosciences
CRBU
$146M
| $65.8K | 0.04% |
12,399
-4,766
| -28% | -$29.7K |
|
411
Design Therapeutics
DSGN
$751M
| $65.8K | 0.04% |
11,396
-4,378
| -28% | -$32.7K |
|
|
ITOS
412
DELISTED
iTeos Therapeutics
ITOS
| $65.1K | 0.04% |
4,782
-1,838
| -28% | -$32.9K |
|
|
INBX
413
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $64.9K | 0.04% |
3,438
-1,323
| -28% | -$30.8K |
|
414
Allogene Therapeutics
ALLO
$625M
| $64.6K | 0.04% |
13,071
-5,026
| -28% | -$32.2K |
|
|
VERV
415
DELISTED
Verve Therapeutics
VERV
| $64.5K | 0.04% |
4,471
-1,724
| -28% | -$33.8K |
|
|
ALLK
416
DELISTED
Allakos
ALLK
| $64.2K | 0.04% |
14,435
-5,546
| -28% | -$35.5K |
|
417
Replimune Group
REPL
$454M
| $64K | 0.04% |
3,623
-1,396
| -28% | -$33.2K |
|
|
AFMD
418
DELISTED
Affimed
AFMD
| $63.9K | 0.04% |
8,575
-3,295
| -28% | -$33K |
|
419
Erasca
ERAS
$6.15B
| $62.9K | 0.03% |
20,902
-8,038
| -28% | -$29.2K |
|
420
Precigen
PGEN
$1.94B
| $62.7K | 0.03% |
59,170
-22,742
| -28% | -$32.8K |
|
|
DAWN
421
DELISTED
Day One Biopharmaceuticals
DAWN
| $62.6K | 0.03% |
4,685
-1,797
| -28% | -$35.1K |
|
|
KLRS
422
Kalaris Therapeutics
KLRS
$80.9M
| $59.5K | 0.03% |
656
-253
| -28% | -$32.2K |
|
423
AtaiBeckley Inc
ATAI
$2.66B
| $59.1K | 0.03% |
32,639
-12,545
| -28% | -$21.2K |
|
|
MRSN
424
DELISTED
Mersana Therapeutics
MRSN
| $58.2K | 0.03% |
567
-218
| -28% | -$30.6K |
|
|
AGEN
425
Agenus
AGEN
$276M
| $57.2K | 0.03% |
1,917
-736
| -28% | -$31.1K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
RC
Virtus ETF Advisers's Q1 2023 Portfolio in Review
As of Q1 2023, Virtus ETF Advisers held 508 positions worth $182M, down 5.1% from $191M the previous quarter. Its ten largest holdings account for 6.2% of the portfolio.
Virtus ETF Advisers withdrew a net $9.6M in Q1 2023, closing 68 positions and reducing 215 holdings. Its most notable exit was Lennar Class A, an estimated $952K position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 26% of assets, down from 27% a quarter earlier, followed by Financials and Technology.
Against the trend, Virtus ETF Advisers opened a new position in Dow Inc worth $1.16M.
- Virtus ETF Advisers's largest Q1 2023 buy was Dow Inc: 21,099 shares worth $1.16M.
- Virtus ETF Advisers added most to Devon Energy in Q1 2023, an estimated $447K increase.
- Virtus ETF Advisers's biggest Q1 2023 reduction was LyondellBasell Industries, cutting an estimated $514K.
- Virtus ETF Advisers fully exited Lennar Class A in Q1 2023, selling an estimated $952K.
- Virtus ETF Advisers's ten largest holdings make up 6.2% of its $182M portfolio in Q1 2023.
- Virtus ETF Advisers opened 65 new positions and closed 68 in Q1 2023.
- Virtus ETF Advisers's portfolio value fell 5.1% quarter-over-quarter to $182M.
Based on Virtus ETF Advisers's 13F filing for Q1 2023, filed 15 May 2023.